The association between the PTPN22 1858CT variant and type 1 diabetes depends on HLA risk and GAD65 autoantibodies

Genes and Immunity

Volumn 11, Issue 5, 2010, Pages 406-415

  Maziarz, M ^a   Janer, M ^b   Roach, J C ^b   Hagopian, W ^c   Palmer, J P ^a   Deutsch, K ^b   Sanjeevi, C B ^d   Kockum, I ^d   Breslow, N ^a   Lernmark, A ^a,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

autoimmune disease; IA 2 autoantibodies; ICA; insulin autoantibodies; islet cell antigen; islet cell autoantibodies

Indexed keywords

GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HLA ANTIGEN; INSULIN ANTIBODY; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PANCREAS ISLET CELL ANTIBODY; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; PTPN22 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DNA MODIFICATION; FEMALE; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; ADOLESCENT; AGE; CHILD; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; IMMUNOLOGY; INFANT; METABOLISM; NEWBORN; PRESCHOOL CHILD; RISK; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGE FACTORS; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLUTAMATE DECARBOXYLASE; HLA ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; RISK ASSESSMENT; SWEDEN;

EID: 77954887535     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2010.12     Document Type: Article

References (57)

1. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 1999; 93: 2013-2024.
2. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Monteiro J et al. A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 2001; 68: 927-936.
3. Bottini NB, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36: 337-338.
4. Begovich AB, Carlton VEH, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75: 330-337.
5. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M et al. Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005; 76: 561-571.
6. De Jager PL, Sawcer S, Waliszewska A, Farwell L, Wild G, Cohen A et al. Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis. Eur J Hum Genet 2006; 14: 317-321.
7. Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 2007; 40: 453-461.
8. Steck AK, Liu S-Y, McFann K, Barriga KJ, Babu SR, Eisenbarth GS et al. Association of the PTPN22/LYP gene with type 1 diabetes. Pediatr Diabetes 2006; 7: 274-278.
9. Ladner MB, Bottini N, Valdes AM, Noble JA. Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes. Hum Immunol 2005; 66: 60-64.
10. Kahles H, Ramos-Lopez E, Lange B, Zwermann O, Reincke M, Badenhoop K. Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population. Eur J Endocrinol 2005; 153: 895-899.
11. Zhernakova A, Eerligh P, Wijmenga C, Barrera P, Roep BO, Koeleman BPC. Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population. Genes Immun 2005; 6: 459-461.
12. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JMM et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53: 3020-3023.
13. Hermann R, Lipponen K, Kiviniemi M, Kakko T, Veijola R, Simell O et al. Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 2006; 49: 1198-1208.
14. Nielsen C, Hansen D, Husby S, Lillevang ST. Sex-specific association of the human PTPN22 1858T allele with type 1 diabetes. Int J Immunogenet 2007; 34: 469-473.
15. Santiago J, Martinez A, de la Calle H, Fernandez-Arquero M, Figueredo MA, de la Concha E et al. Susceptibility to type 1 diabetes conferred by the PTPN22 C1858T polymorphism in the Spanish population. BMC Med Genet 2007; 8: 54.
16. Saccucci P, del Duca E, Rapini N, Verrotti A, Piccinini S, Maccari A et al. Association between PTPN22 C1858T and type 1 diabetes: a replication in continental Italy. Tissue Antigens 2008; 71: 234-237.
17. Cinek O, Hradsky O, Ahmedov G, Slavcev A, Kolouskova S, Kulich M et al. No independent role of the\1123 G>C and +2740 A > G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations. Diabetes Res Clin Pract 2007; 76: 297-303.
18. Fedetz M, Matesanz F, Caro-Maldonado A, Smirnov II, Chvorostinka VN, Moiseenko TA et al. The 1858 T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population. Tissue Antigens 2006; 67: 430-433.
19. Gomez LM, Anaya J-M, Gonzalez CI, Pineda-Tamayo R, Otero W, Arango A et al. PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases. Genes Immun 2005; 6: 628-631.
20. Ikegami H, Kawabata Y, Noso S, Fujisawa T, Ogihara T Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res Clin Pract 2007; 77 (3, Supplement 1): S116-S121.
21. Mori M, Yamada R, Kobayashi K, Kawaida R, Yamamoto K. Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J Hum Genet 2005; 50: 264-266.
22. Smyth DJ, Cooper JD, Howson JM, Walker NM, Plagnol V, Stevens H et al. PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes. Diabetes 2008; 57: 1730-1737.
23. Rolandsson O, Hagg E, Janer M, Rutledge E, Gaur LK, Nilsson M et al. High GAD65 autoantibody levels in nondiabetic adults are associated with HLA but not with CTLA-4 or INS VNTR. J Intern Med 2003; 253: 447-453.
24. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002; 51: 1346-1355.
25. Chelala C, Duchatelet S, Joffret M-L, Bergholdt R, Dubois-Laforgue Dl, Ghandil P et al. PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits. Diabetes 2007; 56: 522-526.
26. Gupta M, Graham J, McNeeny B, Zarghami M, Landin-Olsson M, Hagopian WA et al. MHC class I chain-related gene-A is associated with IA2 and IAA but not GAD in Swedish type 1 diabetes mellitus. Ann N Y Acad Sci 2006; 1079: 229-239.
27. Shin JH, Janer M, McNeney B, Blay S, Deutsch K, Sanjeevi CB et al. IA-2 autoantibodies in incident type I diabetes patients are associated with a polyadenylation signal polymorphism in GIMAP5. Genes Immun 2007; 8: 503-512.
28. Orozco G, Pascual-Salcedo D, Lopez-Nevot MA, Cobo T, Cabezon A, Martin-Mola E et al. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis. Rheumatology 2008; 47: 138-141.
29. Smith A, Bates M. Confidence limit analyses should replace power calculations in the interpretation of epidemiologic studies. Epidemiology (Cambridge, Mass) 1992; 3: 449-452.
30. Mansson L, Torn C, Landin-Olsson M. Islet cell antibodies represent autoimmune response against several antigens. Int J Exp Diabetes Res 2001; 2: 85-90.
31. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases, a meta-analysis. Rheumatology 2007; 46: 49-56.
32. Petrone A, Suraci C, Capizzi M, Giaccari A, Bosi E, Tiberti C et al. The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults. Diabetes Care 2008; 31: 534-538.
33. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoanti-bodies in diabetes. Diabetes 2005; 54: 52-61.
34. Wasserfall CH, Atkinson MA. Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev 2006; 5: 424-428.
35. Rantapaa-Dahlqvist S. What happens before the onset of rheumatoid arthritis? Curr Opin Rheumatol 2009; 21: 272-278.
36. Graham J, Kockum I, Sanjeevi CB, Landin-Olsson M, Nystruom L, Sundkvist G et al. Negative association between type 1 diabetes and HLA DQB1*0602-DQA1*0102 is attenu¬ated with age at onset. Eur J Immunogenet 1999; 26: 117-127.
37. Hansson L, Khamis HJ. Matched samples logistic regression in case-control studies with missing values: when to break the matches. Stat Methods Med Res 2008; 17: 595-607.
38. Larsson HE, Lynch K, Lernmark B, Nilsson A, Hansson G, Almgren P et al. Diabetes-associated HLA genotypes affect birthweight in the general population. Diabetologia 2005; 48: 1484-1491.
39. Kockum I, Sanjeevi CB, Eastman S, Landin-Olsson M, Dahlquist G, Lernmark A. Complex interaction between HLA DR and DQ in conferring risk for childhood type 1 diabetes. Eur J Immunogenet 1999; 26: 361-372.
40. Sanjeevi CB, Lybrand TP, DeWeese C, Landin-Olsson M, Kockum I, Dahlquist G et al. Polymorphic amino acid variations in HLA-DQ are associated with systematic physical property changes and occurrence of IDDM. Members of the Swedish Childhood Diabetes Study. Diabetes 1995; 44: 125-131.
41. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337-1339.
42. Landin-Olsson M, Karlsson FA, Lernmark A, Sundkvist G. Islet cell and thyrogastric antibodies in 633 consecutive 15-to 34-yr-old patients in the diabetes incidence study in Sweden. Diabetes 1992; 41: 1022-1027.
43. Hagopian WA, Karlsen AE, Gottsater A, Landin-Olsson M, Grubin CE, Sundkvist G et al. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest 1993; 91: 368-374.
44. Hagopian WA, Sanjeevi CB, Kockum I, Landin-Olsson M, Karlsen AE, Sundkvist G et al. Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest 1995; 95: 1505-1511.
45. Falorni A, Grubin CE, Takei I, Shimada A, Kasuga A, Maruyama T et al. Radioimmunoassay detects the frequent occurrence of autoantibodies to the Mr 65,000 isoform of glutamic acid decarboxylase in Japanese insulin-dependent diabetes. Autoimmunity 1994; 19: 113-125.
46. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decar-boxylase antibodies in childhood IDDM. Diabetologia 1994; 37: 344-350.
47. Mire-Sluis AR, Gaines Das R, Lernmark A, Participants of the study. The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia 2000; 43: 1282-1292.
48. Lan MS, Lu J, Goto Y, Notkins AL. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 1994; 13: 505-514.
49. Rabin DU, Pleasic SM, Palmer-Crocker R, Shapiro JA. Cloning and expression of IDDM-specific human autoantigens. Dia¬betes 1992; 41: 183-186.
50. Kawasaki E, Eisenbarth GS, Wasmeier C, Hutton JC. Auto-antibodies to protein tyrosine phosphatase-like proteins in type I diabetes: overlapping specificities to phogrin and ICA512/IA-2. Diabetes 1996; 45: 1344-1349.
51. Olsson ML, Sundkvist G, Lernmark A. Prolonged incubation in the two-colour immunofluorescence test increases the preva¬lence and titres of islet cell antibodies in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 327-332.
52. Bonifacio E, Lernmark A, Dawkins RL. Serum exchange and use of dilutions have improved precision of measurement of islet cell antibodies. J Immunol Methods 1988; 106: 83-88.
53. van Belle G, Fisher LD, Heagerty PJ, Lumley T. Biostatistics: A Methodology for the Health Sciences, 2nd edn. John Wiley and Sons, Inc.: Hoboken, NJ, 2004.
54. Agresti A. Categorical Data Analysis, 2nd edn. A John Wiley & Sons, Inc.: Hoboken, New Jersey, 2002.
55. Baniasadi V, Das SN. No evidence for association of PTPN22 R620W functional variant C1858T with type 1 diabetes in Asian Indians. J Cell Mol Med 2008; 12: 1061-1062.
56. Douroudis K, Prans E, Haller K, Nemvalts V, Rajasalu T, Tillmann V et al. Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population. Tissue Antigens 2008; 72: 425-430.
57. Zoledziewska M, Perra C, Orru V, Moi L, Frongia P, Congia M et al. Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes. Diabetes 2008; 57: 229-234.